India Pharma Stocks 2026: FY26 Margins & ROCE Ranked

India's pharmaceutical sector has turned in a strong FY26 on the back of a recovering US generics market, resilient domestic branded-formulations growth, and an expanding CDMO/API export opportunity. Five of India's top pharma stocks — which together account for roughly ₹9.8 lakh crore in combined market capitalisation — sit near their 52-week highs. Yet the quality gap within the group is significant.

We pulled live FY26 annual data from the DocStoX dataset (sourced from NSE/BSE audited annual filings) for all five stocks and ranked them by ROCE and EBITDA margin — the two metrics that determine long-term value creation in a sector where R&D intensity, regulatory-approval timelines, and geographic mix drive divergent outcomes. These are not TTM estimates or modelled projections. Every figure here is from the audited annual (FY26, March 2026) row.

Why Margins and ROCE Matter in Pharma

Pharmaceutical companies invest heavily upfront — in R&D, regulatory filings, manufacturing compliance, and clinical studies — before a single tablet is sold. EBITDA margin tells you how much of each revenue rupee survives after operating costs; ROCE tells you how productively that capital generates operating profit. In an R&D-intensive sector, a company with 30%+ ROCE is compounding its own capital efficiently enough to fund the next drug cycle without constantly diluting shareholders or borrowing. A company at 14% ROCE needs external capital to grow at the same rate.

The five stocks in this analysis span the quality spectrum from world-class API purity (Divi's Labs) to scale-with-specialty (Sun Pharma) to turnaround-driven margin recovery (Dr Reddy's).

ROCE Rankings: The FY26 Scoreboard (July 7, 2026)

All figures are from NSE/BSE audited annual filings (period ending March 2026), pulled from the DocStoX dataset:

• Lupin: 30% ROCE — highest in the group, near-peak price, 21.35x PE
• Divi's Labs: 22% ROCE — pure API/CDMO play, zero debt, 33% EBITDA margin
• Sun Pharma: 21% ROCE — India's largest pharma by revenue, 30% EBITDA margin
• Cipla: 15% ROCE — access-medicine specialist, near-zero debt (D/E 0.02)
• Dr Reddy's: 14% ROCE — cheapest PE at 26.95x, lowest returns in the group

The spread from 30% to 14% within a single sector is not trivial. It reflects fundamentally different business models: Lupin's US branded generics recovery and domestic respiratory franchise have driven a step-change in returns on capital; Dr Reddy's is working through biosimilar investment costs and US pricing headwinds that are compressing near-term ROCE even as the long-term pipeline matures.

Lupin (LUPIN): The Quality-at-Value Story

Lupin is the standout finding in this analysis. At 30% ROCE, 32% EBITDA margin, ROE of 29.1%, and a PE of just 21.35x, it offers a combination that is rare anywhere in Indian large-cap equities: high-quality returns at a non-premium valuation. Revenue of ₹27,958 crore, PAT of ₹5,355 crore (PAT margin 19.15%), and EBITDA of ₹8,816 crore underline a business that has decisively turned around its US generics execution and rebuilt domestic market share.

D/E of 0.29 is the highest in the group but still modest — Lupin carries manageable leverage, the bulk of which funds working capital for its US and India operations rather than unproductive fixed assets. Market cap stands at ₹1.14 lakh crore. The current price of ₹2,490.2 is down just 1.1% from its 52-week high of ₹2,517 — the market has re-rated the stock close to its all-time-best levels as earnings have recovered — yet at 21x PE, Lupin still trades at a discount to every other name in this group except Dr Reddy's. For investors screening India pharma stocks 2026, Lupin's ROCE-to-PE ratio is the most compelling in this set.

Divi's Labs (DIVISLAB): API Purity, 33% EBITDA, Zero Debt — at 70x PE

Divi's Laboratories is the most focused company in this analysis: a pure-play API manufacturing and CDMO business. It runs a completely debt-free balance sheet (D/E 0.0) and delivers the highest EBITDA margin of the group at 33% — a level more associated with software companies than chemical manufacturers. Revenue of ₹10,560 crore and PAT of ₹2,568 crore (PAT margin 24.32%) come from a concentrated, high-quality customer base of global innovator pharma companies that rely on Divi's for regulated API supply.

ROCE of 22% and ROE of 16.5% are strong in absolute terms but trail Lupin — reflecting Divi's greater capital intensity in API manufacturing facilities. The quality is unambiguous, and so is the price. At P/E 70x and a market cap of ₹1.80 lakh crore, Divi's is the most expensive stock in this group — priced for a structural CDMO growth story as global pharma companies accelerate outsourcing to India to reduce China supply-chain dependence. Current price of ₹6,771.5 is down 4.2% from its 52-week high of ₹7,071.5 and up 20.1% from its 52-week low of ₹5,636.5. Dividend yield is 0.45%.

Sun Pharma (SUNPHARMA): India's Largest Pharma — Scale and 30% EBITDA

Sun Pharmaceutical Industries is the sector bellwether. Revenue of ₹58,462 crore — roughly 1.7x the next-largest name in this group (Dr Reddy's) — and PAT of ₹11,509 crore (PAT margin 19.69%) underline its dominance. EBITDA of ₹17,731 crore at a 30% margin is the second-highest margin in the group. ROCE of 21% and ROE of 16% are solid for a company of this scale and complexity.

The business spans branded generics in India and the US, specialty dermatology (Ilumya for psoriasis, Odomzo for skin cancer), a growing proprietary-products segment, and branded hospital formulations in emerging markets. D/E of just 0.06 makes it near debt-free. Market cap stands at ₹4.57 lakh crore — more than the other four stocks combined. At P/E 39.79x, the market prices in Sun's scale premium and specialty-product pipeline. The current price of ₹1,903.4 is down just 1.1% from its 52-week high of ₹1,925.1 — practically at peak. Dividend yield: 0.86%.

Cipla (CIPLA): Access-Medicine Specialist, Mid-Tier Returns

Cipla is the access-medicine champion — a large domestic branded business, a strong US inhalation-generics franchise, and a growing Sub-Saharan Africa HIV generics platform. Revenue of ₹28,163 crore and PAT of ₹3,862 crore (PAT margin 13.71%) reflect a business with slightly lower margin intensity than the top-tier names. EBITDA margin of 21%, ROCE of 15%, and ROE of 11.6% are solid but sit below Lupin and Divi's on quality metrics.

The balance sheet is a standout: D/E of just 0.02 — Cipla is virtually debt-free. That near-zero-leverage positioning, combined with a 30.23x PE and 0.89% dividend yield, makes Cipla the most conservative risk profile in this group. The current price of ₹1,451.8 is down 13.2% from its 52-week high of ₹1,673 — the largest correction in the group — and up 24.5% from its 52-week low of ₹1,165.7. Market cap: ₹1.17 lakh crore. The correction has made Cipla modestly more interesting from a valuation standpoint, though the ROCE gap vs Lupin is real.

Dr Reddy's (DRREDDY): Cheapest PE, But Returns Trail

Dr Reddy's Laboratories offers the lowest PE in the group at 26.95x. Revenue of ₹33,700 crore and PAT of ₹4,158 crore (PAT margin 12.34%) are solid in absolute terms. But ROCE of 14% and ROE of 11.8% are the lowest in the group, reflecting a business that is absorbing significant R&D investment in biosimilars (pegfilgrastim, trastuzumab, rituximab for the US and Europe markets) and navigating US generic-drug pricing pressure in its base portfolio.

D/E of 0.2 is comfortable — Dr Reddy's carries modest leverage. EBITDA margin of 19% is the lowest of the five, though the biosimilar pipeline, if it executes, could drive meaningful margin recovery in FY27-28. At ₹1,354.6, the stock is down 4.3% from its 52-week high of ₹1,414.9. Market cap: ₹1.13 lakh crore. At 27x PE with 14% ROCE, Dr Reddy's is a pipeline-and-recovery bet rather than a current-quality compounder.

FY26 Profitability: The Full Scoreboard

All figures are from NSE/BSE audited annual filings (FY26, March 2026 period), sourced via DocStoX data:

• Sun Pharma: Revenue ₹58,462 Cr | PAT ₹11,509 Cr | PAT Margin 19.7% | EBITDA Margin 30% | ROCE 21% | P/E 39.79x | Mkt Cap ₹4.57 lakh Cr
• Dr Reddy's: Revenue ₹33,700 Cr | PAT ₹4,158 Cr | PAT Margin 12.3% | EBITDA Margin 19% | ROCE 14% | P/E 26.95x | Mkt Cap ₹1.13 lakh Cr
• Cipla: Revenue ₹28,163 Cr | PAT ₹3,862 Cr | PAT Margin 13.7% | EBITDA Margin 21% | ROCE 15% | P/E 30.23x | Mkt Cap ₹1.17 lakh Cr
• Lupin: Revenue ₹27,958 Cr | PAT ₹5,355 Cr | PAT Margin 19.2% | EBITDA Margin 32% | ROCE 30% | P/E 21.35x | Mkt Cap ₹1.14 lakh Cr
• Divi's Labs: Revenue ₹10,560 Cr | PAT ₹2,568 Cr | PAT Margin 24.3% | EBITDA Margin 33% | ROCE 22% | P/E 70x | Mkt Cap ₹1.80 lakh Cr

The most striking observation: Lupin generates nearly the same PAT (₹5,355 crore) as the much larger Dr Reddy's (₹4,158 crore) and Cipla (₹3,862 crore) on comparable revenue, while running higher margins and ROCE — yet trades at a lower PE than either. The PAT-to-PE mismatch between Lupin and its peers is the central quality-vs-valuation tension in India pharma stocks 2026.

Catalysts to Watch in H2 FY27

1. US FDA clearances for complex generics: The US market remains the primary margin driver for Dr Reddy's, Cipla (inhalation), Lupin (respiratory and oral), and Sun Pharma (dermatology). Approval timelines for any pending ANDAs or NDA filings can move earnings in the quarter of approval. Regulatory plant-inspection outcomes are the key watch item.
2. CDMO order pipeline (Divi's Labs): Global innovator pharma companies accelerating outsourcing to India is a structural tailwind for Divi's. Any large new CDMO contract or commercial milestone payment — particularly from a GLP-1 or oncology originator — would be a material positive given Divi's asset-light CDMO model relative to its pure API revenue base.
3. Domestic branded-formulations volume recovery: The National Medical Devices Policy and healthcare spending acceleration post-budget should support volume growth in domestic branded markets. Sun Pharma, Cipla, and Lupin have deep India-branded businesses; urban-rural demand recovery will be a top-line driver in H2 FY27.
4. Biosimilar launches (Dr Reddy's): Dr Reddy's biosimilar pipeline (US/Europe market launches for oncology and supportive-care molecules) is the earnings-recovery lever that justifies its 27x PE with 14% ROCE. Any commercial-scale launch announcement in the US could drive significant earnings-per-share revision.
5. Sun Pharma specialty ramp (Ilumya, dermatology): Sun's US specialty business — which commands significantly higher margins than generics — is its primary re-rating catalyst. Quarterly specialty-segment revenue growth is the number to watch for investors assessing whether the 39.79x PE is justifiable on a margin-expansion story.

The DocStoX Take

India's pharma sector in 2026 splits into three distinct quality profiles:

Quality at a fair price (Lupin): 30% ROCE, 32% EBITDA margin, ROE of 29.1%, and PE of just 21.35x. This is the most unusual combination in the group — comparable quality to Divi's Labs on EBITDA, but priced without the CDMO premium. Lupin's near-52W-high price confirms the market knows the turnaround has worked; the valuation has simply not caught up to the quality of the underlying returns.

Quality at any price (Divi's Labs): 33% EBITDA margin, zero debt, 22% ROCE, and 70x PE. For investors who believe in India's structural CDMO opportunity, Divi's is the purest expression of that thesis. The price already reflects considerable optimism; the upside requires sustained order growth from global innovators.

Scale with complexity discount (Sun Pharma, Cipla, Dr Reddy's): The three larger, more diversified companies carry good but not exceptional ROCE (21%, 15%, 14%), trade at moderate multiples (40x, 30x, 27x), and offer a different kind of optionality — specialty-product upsides, access-medicine scale, and biosimilar pipeline depth respectively.

For investors screening India pharma stocks 2026 on a quality-adjusted-valuation basis, Lupin's ROCE leadership at a below-sector PE is the key data point this analysis surfaces. Full live data, DocStoX AI verdicts, and fair-value estimates for Sun Pharma, Dr Reddy's, Cipla, Lupin, and Divi's Labs are available at docstox.com.

---

By the DocStoX Desk — This is for informational purposes only and not investment advice. Please consult a SEBI-registered advisor before investing.